Patents by Inventor Marco Prinz

Marco Prinz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of multiple sclerosis and/or rheumatoid arthritis
    Patent number: 9068002
    Abstract: The invention relates to the use of an antibody which can specifically bind to chemokine receptor CCR2 for producing a medicament utilized for the treatment of multiple sclerosis and/or rheumatoid arthritis in a subject that is preferably a primate or a human. In another embodiment, the invention relates to the use of an antibody which can specifically bind to chemokine receptor CCR2 for producing a medicament that is utilized for depleting monocytes in subjects suffering from multiple sclerosis and/or rheumatoid arthritis. The invention further relates to corresponding in vitro methods and therapeutic methods. And antibody which binds to CD 14, for example, can be used in addition to the antibody that can bind to CCR2.
    Type: Grant
    Filed: April 2, 2007
    Date of Patent: June 30, 2015
    Assignees: GEORG-AUGUST-UNIVERSITAT GOTTINGEN STIFTUNG OFFENTLICHEN RECHTS, UNIVERSITAT REGENSBURG
    Inventors: Marco Prinz, Wolfgang Bruck, Alexander Mildner, Matthias Mack
  • TREATMENT OF MULTIPLE SCLEROSIS AND/OR RHEUMATOID ARTHRITIS
    Publication number: 20090311273
    Abstract: The invention relates to the use of an antibody which can specifically bind to chemokine receptor CCR2 for producing a medicament utilized for the treatment of multiple sclerosis and/or rheumatoid arthritis in a subject that is preferably a primate or a human. In another embodiment, the invention relates to the use of an antibody which can specifically bind to chemokine receptor CCR2 for producing a medicament that is utilized for depleting monocytes in subjects suffering from multiple sclerosis and/or rheumatoid arthritis. The invention further relates to corresponding in vitro methods and therapeutic methods. And antibody which binds to CD 14, for example, can be used in addition to the antibody that can bind to CCR2.
    Type: Application
    Filed: April 2, 2007
    Publication date: December 17, 2009
    Applicants: Georg-August-Universitat Gottingen Stiftung Offentlichen Rechts, Universitat Regensburg
    Inventors: Marco Prinz, Wolfgang Bruck, Alexander Mildner, Matthias Mack